Richard Markus - 10 Feb 2025 Form 4 Insider Report for Arcus Biosciences, Inc. (RCUS)

Role
Chief Medical Officer
Signature
/s/ Carolyn Tang, Attorney-in-Fact
Issuer symbol
RCUS
Transactions as of
10 Feb 2025
Net transactions value
$0
Form type
4
Filing time
11 Feb 2025, 21:10:58 UTC
Previous filing
11 Feb 2025
Next filing
18 Dec 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCUS Common Stock Award $0 +75,193 $0.000000 75,193 10 Feb 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RCUS Stock Option (right to buy) Award $0 +305,328 $0.000000 305,328 10 Feb 2025 Common Stock 305,328 $12.45 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the grant of restricted stock units that vest in four equal annual installments beginning March 15, 2026, subject to the Reporting Person's continued service to the Company.
F2 The option becomes exercisable in 48 equal monthly installments after February 1, 2025, subject to the Reporting Person's continued service to the Company